O2h provides multi-FTE -synthetic chemistry services to MRCT

MRCT translates cutting edge scientific discoveries into commercial products, two of which (Tysabri and Actemra) are already on the market. The MRCT Centre for Therapeutics Discovery works closely with the MRCT Intellectual Property and Business Development Division and is rigorous in the selection of well‐defined and characterised targets, and considers novelty, validation and ‘druggability’. In addition, the group works on targets where there is a clear strategy for progression and development.

MRCT’s call for targets

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers.

Collaboration between Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg and MRCT

The collaboration will focus on development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).